Indoco Remedies Limited (INDOCO.BO)
INR 337.6
(-0.35%)
INR 337.6
(-0.35%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 6.04 Billion INR | -28.11% |
| 2022 | 11.18 Billion INR | 6.86% |
| 2021 | 10.46 Billion INR | 21.88% |
| 2020 | 8.58 Billion INR | 15.31% |
| 2019 | 7.44 Billion INR | 20.45% |
| 2018 | 6.18 Billion INR | -7.23% |
| 2017 | 6.66 Billion INR | -2.45% |
| 2016 | 6.83 Billion INR | 4.12% |
| 2015 | 6.56 Billion INR | 24.04% |
| 2014 | 5.29 Billion INR | 14.87% |
| 2013 | 4.6 Billion INR | 25.1% |
| 2012 | 3.68 Billion INR | 13.72% |
| 2011 | 3.23 Billion INR | 42.08% |
| 2010 | 2.27 Billion INR | -0.48% |
| 2009 | 2.28 Billion INR | -34.69% |
| 2008 | 3.5 Billion INR | 0.0% |
| 2007 | - INR | -100.0% |
| 2006 | 1.82 Billion INR | -24.85% |
| 2005 | 2.43 Billion INR | 25.38% |
| 2004 | 1.94 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.65 Billion INR | -14.94% |
| 2024 Q2 | 1.74 Billion INR | 5.41% |
| 2023 Q2 | 3.26 Billion INR | 13.24% |
| 2023 Q1 | 2.88 Billion INR | -3.08% |
| 2023 FY | 8.04 Billion INR | -28.11% |
| 2023 Q4 | 1.94 Billion INR | -38.62% |
| 2023 Q3 | 3.16 Billion INR | -3.02% |
| 2022 FY | 11.18 Billion INR | 6.86% |
| 2022 Q1 | 2.63 Billion INR | 0.4% |
| 2022 Q2 | 2.77 Billion INR | 5.49% |
| 2022 Q3 | 2.8 Billion INR | 1.17% |
| 2022 Q4 | 2.97 Billion INR | 5.87% |
| 2021 Q2 | 2.66 Billion INR | -1.67% |
| 2021 Q1 | 2.71 Billion INR | 34.46% |
| 2021 FY | 10.46 Billion INR | 21.88% |
| 2021 Q3 | 2.4 Billion INR | -9.92% |
| 2021 Q4 | 2.62 Billion INR | 9.12% |
| 2020 FY | 8.58 Billion INR | 15.31% |
| 2020 Q1 | 1.85 Billion INR | -0.48% |
| 2020 Q4 | 2.01 Billion INR | -15.74% |
| 2020 Q3 | 2.39 Billion INR | 2.78% |
| 2020 Q2 | 2.32 Billion INR | 25.74% |
| 2019 FY | 7.44 Billion INR | 20.45% |
| 2019 Q3 | 2 Billion INR | 2.04% |
| 2019 Q1 | 1.61 Billion INR | 0.67% |
| 2019 Q4 | 1.86 Billion INR | -7.26% |
| 2019 Q2 | 1.96 Billion INR | 21.69% |
| 2018 Q3 | 1.59 Billion INR | 2.04% |
| 2018 Q1 | 1.41 Billion INR | 0.0% |
| 2018 FY | 6.18 Billion INR | -7.23% |
| 2018 Q4 | 1.6 Billion INR | 0.4% |
| 2018 Q2 | 1.56 Billion INR | 10.73% |
| 2017 FY | 6.66 Billion INR | -2.45% |
| 2016 FY | 6.83 Billion INR | 4.12% |
| 2015 FY | 6.56 Billion INR | 24.04% |
| 2014 Q1 | 1.26 Billion INR | 0.0% |
| 2014 FY | 5.29 Billion INR | 14.87% |
| 2013 Q1 | 942.8 Million INR | 34.69% |
| 2013 FY | 4.6 Billion INR | 25.1% |
| 2012 Q4 | 699.96 Million INR | 0.0% |
| 2012 FY | 3.68 Billion INR | 13.72% |
| 2011 FY | 3.23 Billion INR | 42.08% |
| 2010 FY | 2.27 Billion INR | -0.48% |
| 2009 FY | 2.28 Billion INR | -34.69% |
| 2008 FY | 3.5 Billion INR | 0.0% |
| 2007 FY | - INR | -100.0% |
| 2006 FY | 1.82 Billion INR | -24.85% |
| 2005 FY | 2.43 Billion INR | 25.38% |
| 2004 FY | 1.94 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | 71.319% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -288.127% |
| Sigachi Industries Limited | 2 Billion INR | -201.722% |
| Bal Pharma Limited | 770.19 Million INR | -684.388% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 2.471% |
| Medico Remedies Limited | 262.14 Million INR | -2204.581% |
| Lasa Supergenerics Limited | 121.02 Million INR | -4891.59% |
| Venus Remedies Limited | 2.18 Billion INR | -176.797% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 1102.865% |
| Alpa Laboratories Limited | 188.89 Million INR | -3098.243% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -103.27% |
| Shilpa Medicare Limited | 3.54 Billion INR | -70.329% |
| Aarti Drugs Limited | 8.31 Billion INR | 27.355% |
| Lupin Limited | 123.71 Billion INR | 95.117% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 96.094% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 95.175% |
| Windlas Biotech Limited | 1.33 Billion INR | -351.249% |
| Suven Life Sciences Limited | -200.79 Million INR | 3108.671% |
| Eris Lifesciences Limited | 10.42 Billion INR | 42.06% |
| Valiant Laboratories Limited | -60.66 Million INR | 10058.659% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 73.386% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -601.5% |
| Ipca Laboratories Limited | 29.8 Billion INR | 79.734% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -63.481% |
| Achyut Healthcare Limited | 4.86 Million INR | -124181.444% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 97.663% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -310.47% |
| RPG Life Sciences Limited | 2.48 Billion INR | -143.307% |
| Mankind Pharma Limited | 44.52 Billion INR | 86.43% |
| Laurus Labs Limited | 24.62 Billion INR | 75.462% |
| Piramal Pharma Limited | 24.47 Billion INR | 75.312% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -541.058% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 87.079% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 77.442% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 91.287% |
| Unichem Laboratories Limited | 4.86 Billion INR | -24.181% |
| Sequent Scientific Limited | 2.97 Billion INR | -102.815% |
| Novartis India Limited | 1.32 Billion INR | -355.296% |
| Wanbury Limited | 1.73 Billion INR | -249.08% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -46.518% |
| Wockhardt Limited | 16.24 Billion INR | 62.8% |
| Themis Medicare Limited | 1.5 Billion INR | -301.709% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -825.745% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 69.244% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 51.409% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 96.307% |
| Divi's Laboratories Limited | 32.44 Billion INR | 81.377% |
| NATCO Pharma Limited | 25.73 Billion INR | 76.526% |
| Gufic Biosciences Limited | 4.16 Billion INR | -44.956% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | -31.884% |
| Ind-Swift Limited | 2.17 Billion INR | -178.078% |
| Procter & Gamble Health Limited | 5.78 Billion INR | -4.496% |
| FDC Limited | 8.33 Billion INR | 27.516% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -3034.652% |
| Granules India Limited | 16.79 Billion INR | 64.038% |
| Medicamen Biotech Limited | 495.49 Million INR | -1119.25% |
| Alkem Laboratories Limited | 52.29 Billion INR | 88.448% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 2.915% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -41336.525% |
| Brooks Laboratories Limited | 65.62 Million INR | -9106.524% |
| Megasoft Limited | 342.07 Million INR | -1666.101% |
| ZIM Laboratories Limited | 1.26 Billion INR | -376.863% |
| Strides Pharma Science Limited | 14.38 Billion INR | 58.012% |
| Neuland Laboratories Limited | 8.24 Billion INR | 26.753% |
| Morepen Laboratories Limited | 6.16 Billion INR | 1.947% |
| Hikal Limited | 3.14 Billion INR | -92.21% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | -3.601% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -873.658% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -758.624% |
| Hester Biosciences Limited | 1.27 Billion INR | -374.331% |